Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
854 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07672392 | The Effect of a Post-operative Exercise Programme Versus Standard Care on Physical Fitness of Patients With Breast Cancer Undergoing Deep Inferior Epigastric Perforator (DIEP) Flap Reconstruction Surgery(EXERCISE DIEP) | recruiting | N/A | 78 | Royal College of Surgeons, IrelandOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT01251861 | Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer | completed | Phase 2 | 108 | National Cancer Institute (NCI)NIH |
| 2 |
| Jun 25, 2026 |
| clinicaltrials |
| NCT05050162 | Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer | suspended | Phase 2 / Phase 3 | 1,714 | NRG OncologyOTHER | 5 | Jun 25, 2026 | clinicaltrials |
| NCT00324805 | Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery | completed | Phase 3 | 1,501 | National Cancer Institute (NCI)NIH | 5 | Jun 23, 2026 | clinicaltrials |
| NCT04475939 | Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer(ZEAL-1L) | completed | Phase 3 | 666 | GlaxoSmithKlineINDUSTRY | 27 | Jun 18, 2026 | clinicaltrials |
| NCT04623775 | A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 468 | Bristol-Myers SquibbINDUSTRY | 19 | Jun 18, 2026 | clinicaltrials |
| NCT04961996 | A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | active not recruiting | Phase 3 | 4,170 | Hoffmann-La RocheINDUSTRY | 54 | Jun 17, 2026 | clinicaltrials |
| NCT02375204 | Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors | active not recruiting | Phase 3 | 420 | Alliance for Clinical Trials in OncologyOTHER | 12 | Jun 16, 2026 | clinicaltrials |
| NCT02513394 | PALbociclib CoLlaborative Adjuvant Study(PALLAS) | active not recruiting | Phase 3 | 5,796 | Alliance Foundation Trials, LLC.OTHER | 21 | Jun 15, 2026 | clinicaltrials |
| NCT05950945 | Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer | recruiting | Phase 3 | 250 | Daiichi SankyoINDUSTRY | 10 | Jun 12, 2026 | clinicaltrials |
| NCT03516981 | A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) | completed | Phase 2 | 245 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Jun 8, 2026 | clinicaltrials |
| NCT05243797 | Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation(MajesTEC-4) | recruiting | Phase 3 | 1,594 | European Myeloma Network B.V.NETWORK | 25 | Jun 4, 2026 | clinicaltrials |
| NCT07076121 | A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) | active not recruiting | Phase 2 / Phase 3 | 470 | Bristol-Myers SquibbINDUSTRY | 36 | Jun 3, 2026 | clinicaltrials |
| NCT02883049 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations | completed | Phase 3 | 5,949 | National Cancer Institute (NCI)NIH | 7 | Jun 2, 2026 | clinicaltrials |
| NCT04527991 | Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread(TROPiCS-04) | completed | Phase 3 | 711 | Gilead SciencesINDUSTRY | 27 | Jun 2, 2026 | clinicaltrials |
| NCT05445778 | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer(GLORIOSA) | active not recruiting | Phase 3 | 520 | AbbVieINDUSTRY | 22 | Jun 2, 2026 | clinicaltrials |
| NCT07230535 | Evaluation of Wellbeing and Patient Reported Outcomes After Open vs Robotic Mastectomy With DIEP Reconstruction(REBORN) | recruiting | N/A | 250 | Beaumont HospitalOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07616245 | MCT Enteral Feeding to Reduce Chyle Leak After Oesophagectomy | recruiting | N/A | 160 | Royal College of Surgeons, IrelandOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07616258 | Evaluating the De-Escalation of Surveillance for Patients Who Have Undergone Curative Treatment for Primary Breast Cancer(De-Escalation) | recruiting | N/A | 560 | Royal College of Surgeons, IrelandOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT01190930 | Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma | completed | Phase 3 | 9,350 | Children's Oncology GroupNETWORK | 7 | May 28, 2026 | clinicaltrials |
| NCT03106324 | A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant | completed | — | 911 | CelgeneINDUSTRY | 12 | May 28, 2026 | clinicaltrials |
| NCT02231749 | Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) | completed | Phase 3 | 1,096 | Bristol-Myers SquibbINDUSTRY | 28 | May 27, 2026 | clinicaltrials |
| NCT04529122 | A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test | completed | — | 7,864 | Hoffmann-La RocheINDUSTRY | 32 | May 27, 2026 | clinicaltrials |
| NCT04704934 | Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) | active not recruiting | Phase 3 | 490 | Daiichi SankyoINDUSTRY | 24 | May 27, 2026 | clinicaltrials |
| NCT05052801 | Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression(FORTITUDE-101) | completed | Phase 3 | 547 | AmgenINDUSTRY | 37 | May 27, 2026 | clinicaltrials |
| NCT07605936 | Frailty in Older Adults With Prostate Cancer: a Prospective Cohort Study | recruiting | — | 80 | University of LimerickOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT02254278 | Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer | completed | Phase 2 | 316 | NRG OncologyOTHER | 4 | May 22, 2026 | clinicaltrials |
| NCT03151629 | International Registry for Men With Advanced Prostate Cancer (IRONMAN)(IRONMAN) | recruiting | — | 5,000 | Prostate Cancer Clinical Trials ConsortiumOTHER | 15 | May 22, 2026 | clinicaltrials |
| NCT03260894 | Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) | completed | Phase 3 | 129 | Incyte CorporationINDUSTRY | 20 | May 22, 2026 | clinicaltrials |
| NCT05186753 | (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis | active not recruiting | Phase 2 | 237 | Cogent Biosciences, Inc.INDUSTRY | 15 | May 22, 2026 | clinicaltrials |
| NCT05149755 | Evolut™ EXPAND TAVR II Pivotal Trial | active not recruiting | N/A | 650 | Medtronic CardiovascularINDUSTRY | 16 | May 19, 2026 | clinicaltrials |
| NCT06760637 | Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease(FourLight-3) | active not recruiting | Phase 3 | 1,035 | PfizerINDUSTRY | 30 | May 19, 2026 | clinicaltrials |
| NCT03409614 | Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer | completed | Phase 3 | 789 | Regeneron PharmaceuticalsINDUSTRY | 18 | May 18, 2026 | clinicaltrials |
| NCT04002297 | A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation(MANGROVE) | active not recruiting | Phase 3 | 510 | BeOne MedicinesINDUSTRY | 22 | May 18, 2026 | clinicaltrials |
| NCT04421820 | BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 220 | Bold Therapeutics, Inc.INDUSTRY | 7 | May 18, 2026 | clinicaltrials |
| NCT07592234 | Chemokeyp: A Feasibility Study for Realtime Safety Data-Capture for Potential Serious Adverse Drug Events | recruiting | — | 100 | St Vincent's University Hospital, IrelandOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT04622319 | A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) | active not recruiting | Phase 3 | 1,600 | Daiichi SankyoINDUSTRY | 31 | May 15, 2026 | clinicaltrials |
| NCT05239728 | A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) | active not recruiting | Phase 3 | 1,800 | Merck Sharp & Dohme LLCINDUSTRY | 32 | May 15, 2026 | clinicaltrials |
| NCT07196020 | Prediction of Venous Thrombosis During chemotherapy-the PINPOINT Study(PINPOINT) | recruiting | — | 380 | University of Dublin, Trinity CollegeOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07244341 | A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) | recruiting | Phase 1 | 60 | Daiichi SankyoINDUSTRY | 4 | May 15, 2026 | clinicaltrials |
| NCT05566795 | DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) | active not recruiting | Phase 3 | 418 | Day One Biopharmaceuticals, Inc.INDUSTRY | 30 | May 14, 2026 | clinicaltrials |
| NCT06284317 | A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.(ADOPT-lung) | recruiting | Phase 3 | 290 | ETOP IBCSG Partners FoundationNETWORK | 10 | May 14, 2026 | clinicaltrials |
| NCT03017326 | Paediatric Hepatic International Tumour Trial(PHITT) | active not recruiting | Phase 3 | 450 | University of BirminghamOTHER | 14 | May 13, 2026 | clinicaltrials |
| NCT03844048 | An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | active not recruiting | Phase 3 | 165 | AbbVieINDUSTRY | 23 | May 13, 2026 | clinicaltrials |
| NCT01101425 | Male Breast Cancer: Understanding the Biology for Improved Patient Care | active not recruiting | — | 200 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 16 | May 12, 2026 | clinicaltrials |
| NCT02308527 | Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children(BEACON) | completed | Phase 2 | 225 | University of BirminghamOTHER | 10 | May 12, 2026 | clinicaltrials |
| NCT04116047 | CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)(CompARE) | active not recruiting | Phase 3 | 785 | University of BirminghamOTHER | 2 | May 7, 2026 | clinicaltrials |
| NCT07164313 | A Study of ZW251 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zymeworks BC Inc.INDUSTRY | 6 | May 7, 2026 | clinicaltrials |
| NCT07572370 | Evaluating the De-Escalation of Surveillance for Patients Who Have Undergone Curative Treatment for Breast Cancer(De-Escalation) | recruiting | — | 560 | Royal College of Surgeons, IrelandOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT02446444 | Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer(ENZARAD) | active not recruiting | Phase 3 | 802 | University of SydneyOTHER | 9 | May 6, 2026 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials